GRO Biosciences: New amino acids for better biologics could reverse autoimmune disease
Image credit: GRO Biosciences
Protein therapeutics are a powerful class of drugs that use proteins to treat various diseases and conditions. However they also have challenges potentially triggering an immune response in the body, maintaining a stable structure, and scalable manufacturing. These challenges have limited the development and application of protein therapeutics, but a new technology is changing the game: synthetic biology.
One of the leading companies using synthetic biology to tackle the challenges of protein therapeutics is GRO Biosciences (GRObio), a prior investment by our team.
GRObio has developed a platform that enables the incorporation of non-standard amino acids (NSAAs) into proteins, to give them previously unattainable therapeutic capabilities, such as precise regulation of the immune system and unprecedented duration of action.
Recently GRO Biosciences presented successful proof of concept results, demonstrating the therapeutic potential and the underlying mechanism of ProGly. These data show promising new modalities for reversing autoimmune disease without immunosuppression and for eliminating anti-drug antibodies against immunogenic therapies.
GRObio is using its innovative platform and NSAAs to transform treatments in diverse areas, such as autoimmune and metabolic diseases. The company is now advancing its programs towards the clinic, with the goal of bringing these novel protein therapeutics to patients.
For more:
